Table 1.

Disease course and therapy of patients affected by severe combined immunodeficiencies and vaccinated with BCG. Adapted from [6].

Cohort	n (%)	Anti-Mycobacterial Therapy
Vaccinated patients	349	238/349 (68%)
BCG-related disease	177/349 (51%)	160/177 (90%)
Disseminated	118/177 (34%)	107/118 (90%)
Localized	59/177 (17%)	53/59 (89%)
No BCG-related disease	172/349 (49%)	78/172 (45%)
SCID treatment and IRIS
HSCT/GT/Thymus transplantation/ERT (% of total patients)	184/3/1/2 (54%)
IRIS	55/190 (29%)
Previously symptomatic for BCG-related disease	47/55 (85%)